Versor Investments LP purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 8,807 shares of the company's stock, valued at approximately $791,000.
A number of other hedge funds also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. bought a new stake in Axsome Therapeutics in the second quarter valued at about $27,000. EntryPoint Capital LLC acquired a new stake in Axsome Therapeutics during the first quarter valued at approximately $35,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Axsome Therapeutics in the 2nd quarter valued at approximately $47,000. Russell Investments Group Ltd. raised its holdings in shares of Axsome Therapeutics by 5,550.0% in the 1st quarter. Russell Investments Group Ltd. now owns 791 shares of the company's stock worth $63,000 after buying an additional 777 shares in the last quarter. Finally, Covestor Ltd raised its holdings in shares of Axsome Therapeutics by 54,750.0% in the 1st quarter. Covestor Ltd now owns 1,097 shares of the company's stock worth $88,000 after buying an additional 1,095 shares in the last quarter. Institutional investors own 81.49% of the company's stock.
Axsome Therapeutics Trading Up 0.1 %
AXSM stock traded up $0.13 during midday trading on Wednesday, reaching $99.62. The stock had a trading volume of 635,052 shares, compared to its average volume of 618,311. Axsome Therapeutics, Inc. has a twelve month low of $56.66 and a twelve month high of $105.00. The business has a fifty day simple moving average of $90.55 and a two-hundred day simple moving average of $83.95. The company has a quick ratio of 2.40, a current ratio of 2.48 and a debt-to-equity ratio of 1.77. The firm has a market cap of $4.73 billion, a price-to-earnings ratio of -15.82 and a beta of 1.26.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping analysts' consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 117.46% and a negative net margin of 105.85%. The business had revenue of $104.76 million during the quarter, compared to analysts' expectations of $98.71 million. During the same period in the previous year, the firm earned ($1.32) earnings per share. As a group, research analysts expect that Axsome Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on AXSM shares. Royal Bank of Canada upped their price target on Axsome Therapeutics from $130.00 to $131.00 and gave the company an "outperform" rating in a research report on Friday, October 4th. StockNews.com lowered shares of Axsome Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday. UBS Group dropped their target price on shares of Axsome Therapeutics from $107.00 to $105.00 and set a "buy" rating for the company in a research report on Tuesday, August 6th. Robert W. Baird upped their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an "outperform" rating in a research note on Wednesday. Finally, Wells Fargo & Company started coverage on shares of Axsome Therapeutics in a research note on Tuesday, September 3rd. They issued an "overweight" rating and a $140.00 target price for the company. One investment analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $124.93.
Read Our Latest Research Report on Axsome Therapeutics
Insider Transactions at Axsome Therapeutics
In related news, Director Mark E. Saad sold 11,016 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total value of $1,005,870.96. Following the sale, the director now directly owns 10,002 shares in the company, valued at $913,282.62. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 22.40% of the company's stock.
Axsome Therapeutics Profile
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Read More
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
